Kirsten White

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Paul E. Sax, Edwin DeJesus, Anthony Mills et al. · The Lancet · 2012 · 444 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Paul E. Sax, Anton Pozniak, Marisa Montes et al. · The Lancet · 2017 · 395 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Joel E. Gallant, Adriano Lazzarin, Anthony Mills et al. · The Lancet · 2017 · 380 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Edwin DeJesus, Jürgen K. Rockstroh, Keith Henry et al. · The Lancet · 2012 · 346 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

Manuel Tsiang, G.S. Jones, Joshua Goldsmith et al. · Antimicrobial Agents and Chemotherapy · 2016 · 283 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17